These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36655608)

  • 21. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.
    Dombret H; Seymour JF; Butrym A; Wierzbowska A; Selleslag D; Jang JH; Kumar R; Cavenagh J; Schuh AC; Candoni A; Récher C; Sandhu I; Bernal del Castillo T; Al-Ali HK; Martinelli G; Falantes J; Noppeney R; Stone RM; Minden MD; McIntyre H; Songer S; Lucy LM; Beach CL; Döhner H
    Blood; 2015 Jul; 126(3):291-9. PubMed ID: 25987659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Azacitidine in adult patients with acute myeloid leukemia.
    Schuh AC; Döhner H; Pleyer L; Seymour JF; Fenaux P; Dombret H
    Crit Rev Oncol Hematol; 2017 Aug; 116():159-177. PubMed ID: 28693797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.
    Fenaux P; Mufti GJ; Hellström-Lindberg E; Santini V; Gattermann N; Germing U; Sanz G; List AF; Gore S; Seymour JF; Dombret H; Backstrom J; Zimmerman L; McKenzie D; Beach CL; Silverman LR
    J Clin Oncol; 2010 Feb; 28(4):562-9. PubMed ID: 20026804
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The euphoria of hypomethylating agents in MDS and AML: is it justified?
    Sekeres MA
    Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Venetoclax combined with azacitidine in the treatment of elderly patients with acute myeloid leukemia or myeloid sarcoma: Three cases reports and literature review].
    Tian FQ; Zhang LS; Li JH; Tang MQ; Jiang J; Cheng XH; Zhang XC; Jiang M
    Zhonghua Xue Ye Xue Za Zhi; 2020 Aug; 41(8):694-696. PubMed ID: 32942828
    [No Abstract]   [Full Text] [Related]  

  • 26. A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients.
    Cooper BW; Kindwall-Keller TL; Craig MD; Creger RJ; Hamadani M; Tse WW; Lazarus HM
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):428-432.e2. PubMed ID: 25776192
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
    Seymour JF; Döhner H; Butrym A; Wierzbowska A; Selleslag D; Jang JH; Kumar R; Cavenagh J; Schuh AC; Candoni A; Récher C; Sandhu I; Del Castillo TB; Al-Ali HK; Falantes J; Stone RM; Minden MD; Weaver J; Songer S; Beach CL; Dombret H
    BMC Cancer; 2017 Dec; 17(1):852. PubMed ID: 29241450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.
    Sekeres MA; Watts J; Radinoff A; Sangerman MA; Cerrano M; Lopez PF; Zeidner JF; Campelo MD; Graux C; Liesveld J; Selleslag D; Tzvetkov N; Fram RJ; Zhao D; Bell J; Friedlander S; Faller DV; Adès L
    Leukemia; 2021 Jul; 35(7):2119-2124. PubMed ID: 33483617
    [No Abstract]   [Full Text] [Related]  

  • 29. 5-Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy.
    Ivanoff S; Gruson B; Chantepie SP; Lemasle E; Merlusca L; Harrivel V; Charbonnier A; Votte P; Royer B; Marolleau JP
    Am J Hematol; 2013 Jul; 88(7):601-5. PubMed ID: 23619977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Role of Azacitidine in the Treatment of Elderly Patients with Acute Myeloid Leukemia: Results of a Retrospective Multicenter Study.
    Tombak A; Uçar MA; Akdeniz A; Tiftik EN; Gören Şahin D; Akay OM; Yıldırım M; Nevruz O; Kis C; Gürkan E; Solmaz ŞM; Özcan MA; Yıldırım R; Berber İ; Erkurt MA; Fıratlı Tuğlular T; Tarkun P; Yavaşoğlu İ; Doğu MH; Sarı İ; Merter M; Özcan M; Yıldızhan E; Kaynar L; Mehtap Ö; Uysal A; Şahin F; Salim O; Sungur MA
    Turk J Haematol; 2016 Dec; 33(4):273-280. PubMed ID: 27095141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia.
    Keating GM
    Drugs; 2012 May; 72(8):1111-36. PubMed ID: 22571445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients.
    Huls G; Chitu DA; Havelange V; Jongen-Lavrencic M; van de Loosdrecht AA; Biemond BJ; Sinnige H; Hodossy B; Graux C; Kooy RVM; de Weerdt O; Breems D; Klein S; Kuball J; Deeren D; Terpstra W; Vekemans MC; Ossenkoppele GJ; Vellenga E; Löwenberg B;
    Blood; 2019 Mar; 133(13):1457-1464. PubMed ID: 30630862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
    Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
    Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduction of Extramedullary Complications in Patients With Acute Myeloid Leukemia/Myelodysplastic Syndrome Treated With Azacitidine.
    Shabanova I; Cada M; Johnston DL; Abbott LS; Leung EW; Schechter T; Dror Y; Klaassen RJ
    J Pediatr Hematol Oncol; 2020 Apr; 42(3):170-174. PubMed ID: 32134844
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
    Gao S; Li Z; Fu JH; Hu XH; Xu Y; Jin ZM; Tang XW; Han Y; Chen SN; Sun AN; Wu DP; Qiu HY
    Asian Pac J Cancer Prev; 2015; 16(15):6627-32. PubMed ID: 26434886
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study.
    Garcia-Manero G; Abaza Y; Takahashi K; Medeiros BC; Arellano M; Khaled SK; Patnaik M; Odenike O; Sayar H; Tummala M; Patel P; Maness-Harris L; Stuart R; Traer E; Karamlou K; Yacoub A; Ghalie R; Giorgino R; Atallah E
    Blood Adv; 2019 Feb; 3(4):508-518. PubMed ID: 30760466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
    DiNardo CD; Daver N; Jabbour E; Kadia T; Borthakur G; Konopleva M; Pemmaraju N; Yang H; Pierce S; Wierda W; Bueso-Ramos C; Patel KP; Cortes JE; Ravandi F; Kantarjian HM; Garcia-Manero G
    Lancet Haematol; 2015 Jan; 2(1):e12-20. PubMed ID: 26687423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia.
    Ritchie EK; Feldman EJ; Christos PJ; Rohan SD; Lagassa CB; Ippoliti C; Scandura JM; Carlson K; Roboz GJ
    Leuk Lymphoma; 2013 Sep; 54(9):2003-7. PubMed ID: 23270581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical response to azacitidine therapy depends on microRNA-29c (miR-29c) expression in older acute myeloid leukemia (AML) patients.
    Butrym A; Rybka J; Baczyńska D; Poręba R; Kuliczkowski K; Mazur G
    Oncotarget; 2016 May; 7(21):30250-7. PubMed ID: 26862847
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.
    Estey EH
    Leukemia; 2013 Sep; 27(9):1803-12. PubMed ID: 23757301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.